2 ms·
Pharmasset spent in the ballpark of $1 billion developing the candidate that Gilead decided to buy (I'm taking the annual spend on total operations there, round
by maxerickson 11y ago
Pharmasset spent in the ballpark of $1 billion developing the candidate that Gilead decided to buy (I'm taking the annual spend on total operations there, rounding up to $100 million and multiplying by 10 to get the $1 billion).
https://www.sec.gov/Archives/edgar/data/882095/000119312511331318/d260880dex991.htm https://www.sec.gov/Archives/edgar/data/882095/0001193125113...
It sort of looks like they have figured out how to have excellent pricing power when they are willing to bid $11 billion for the company. Part of that is probably that looking just at this drug is a facile analysis of the value of Pharmasset (which did more than develop 1 drug, they built expertise in creating antivirals). Of course, the expertise story implies that they don't need to recover the purchase on just this drug.
I guess some of it is the complexity in the medical payments system.